13 Publicly Traded Biotechs Utilizing AI-based Research Platforms (+ 2 Upcoming Public Debuts)
According to our intelligence report, The State of Artificial Intelligence (AI) in the Biopharma Industry, more than 450 life sciences companies in the categories "startups" and "scaleups" are actively using machine learning and deep learning-based predictive and generative capabilities to augment their research strategies.
Some companies are incorporating AI tools to improve specific stages of drug discovery and development, for instance, to better model disease mechanisms or identify drug repurposing opportunities by analyzing omics data. Other companies are building entire end-to-end platforms for hypothesis generation, target discovery, de novo drug design, and even predicting clinical trial outcomes for newly designed candidates.
Below is a list of publicly traded companies with AI-powered platforms, and there is a bonus list of two companies at the end that are currently filing for IPOs.
Topics: AI & Digital